Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease.
Recent advances in our understanding of the role of cytokine networks in inflammatory processes have led to the development of novel biological agents for the treatment of chronic inflammatory diseases. At the present time, significant efforts are focused on characterizing the complex signal transduction cascades that are activated by these cytokines and, in turn, regulate their expression. The transcription factor NF-kappaB is a pivotal regulator of the inducible expression of key proinflammatory mediators, and activated NF-kappaB has been observed in several debilitating inflammatory disorders, including rheumatoid arthritis and osteoarthritis. In light of its central role in inflammation, the identification of inhibitors of NF-kappaB should provide novel therapeutics for the treatment of chronic joint disease.
Roshak
Amy K
AK
Department of COPD Biology, UW 2532, GlaxoSmithKline, 709 Swedeland Rd, King of Prussia, PA 19406-0939, USA. amy.k.roshak@gsk.com
Callahan
James F
JF
Blake
Simon M
SM
D000818:Animals; D001168:Arthritis / Q000188:drug therapy* / Q000473:pathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000502:physiology; D010003:Osteoarthritis / Q000188:drug therapy / Q000473:pathology
D016328:NF-kappa B